Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAF1 | P21675 | 20/20 | 0.81 |
| ▸ | CECR2 | Q9BXF3 | 20/20 | 0.81 |
| ▸ | BRD9 | Q9H8M2 | 20/20 | 0.81 |
| ▸ | BRD4 | O60885 | 19/20 | 0.81 |
| ▸ | TAF11 | Q15544 | 1/20 | 0.61 |
| ▸ | TAF1L | Q8IZX4 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30373817 | 1.00 | TAF1 (0.81) | TAF1CECR2BRD9BRD4TAF11 | |
| SCHEMBL17758434 | 0.90 | TAF1 (1.00) | TAF1CECR2BRD9BRD4TAF11 | |
| SCHEMBL17749793 | 0.88 | TAF1 (1.00) | TAF1CECR2BRD9BRD4TAF11 | |
| SCHEMBL17749882 | 0.82 | TAF1 (1.00) | TAF1CECR2BRD9BRD4TAF11 | |
| SCHEMBL30073356 | 0.82 | CECR2 (0.55) | TAF1CECR2BRD9BRD4TAF11 | |
| SCHEMBL17758548 | 0.82 | CECR2 (0.55) | TAF1CECR2BRD9BRD4TAF11 | |
| SCHEMBL17758433 | 0.80 | TAF1 (1.00) | TAF1CECR2BRD9BRD4TAF11 | |
| SCHEMBL30073306 | 0.79 | CECR2 (1.00) | TAF1CECR2BRD9BRD4 | |
| SCHEMBL19640297 | 0.79 | CECR2 (1.00) | TAF1CECR2BRD9BRD4 | |
| SCHEMBL17758607 | 0.78 | CECR2 (1.00) | TAF1CECR2BRD9BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3218375-B1 | SUBSTITUTED PYRROLOPYRDINES AS INHIBITORS OF BROMODOMAIN | GENENTECH INC (US) | 2022-04-27 | — | — | EP | disclosed |
| US-10183009-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183009-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRPF3 | TAF1 437/4885CECR2 246/4885BRD9 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.